Among the various immunotherapeutic approaches, blockade of immune checkpoint proteins, specifically PD-1/PD-L1 (CD279/CD274), has shown impressive effectiveness in various cancer types, including melanoma (Hamid et al. 2013), lung cancer (Reck et al. 2016), and colorectal cancer (Hu et al. 2022). The gene discussed is PDCD1; the disease is lung cancer.